ATE275398T1 - Valproat-formulierungen mit gesteuerter freigabe - Google Patents

Valproat-formulierungen mit gesteuerter freigabe

Info

Publication number
ATE275398T1
ATE275398T1 AT01310755T AT01310755T ATE275398T1 AT E275398 T1 ATE275398 T1 AT E275398T1 AT 01310755 T AT01310755 T AT 01310755T AT 01310755 T AT01310755 T AT 01310755T AT E275398 T1 ATE275398 T1 AT E275398T1
Authority
AT
Austria
Prior art keywords
composition
valproate
controlled release
significantly lower
cmax
Prior art date
Application number
AT01310755T
Other languages
English (en)
Inventor
Yihong Qiu
Daniel J Bollinger
Sandeep Dutta
Howard S Cheskin
Kevin R Engh
Richard P Poska
Kenneth W Sommerville
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/748,566 external-priority patent/US6528090B2/en
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE275398T1 publication Critical patent/ATE275398T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AT01310755T 2000-12-22 2001-12-21 Valproat-formulierungen mit gesteuerter freigabe ATE275398T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/748,566 US6528090B2 (en) 1998-12-18 2000-12-22 Controlled release formulation of divalproex sodium
US09/877,682 US20020025341A1 (en) 1998-12-18 2001-06-08 Controlled release formulation of divalproex sodium
CA002399532A CA2399532A1 (en) 1998-12-18 2002-08-23 Controlled release formulation of divalproex sodium

Publications (1)

Publication Number Publication Date
ATE275398T1 true ATE275398T1 (de) 2004-09-15

Family

ID=32930833

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01310755T ATE275398T1 (de) 2000-12-22 2001-12-21 Valproat-formulierungen mit gesteuerter freigabe

Country Status (10)

Country Link
US (1) US20020025341A1 (de)
EP (1) EP1216704B1 (de)
AT (1) ATE275398T1 (de)
AU (1) AU2002239260A1 (de)
CA (1) CA2399532A1 (de)
DE (1) DE60105381T2 (de)
ES (1) ES2228762T3 (de)
PT (1) PT1216704E (de)
TR (1) TR200402549T4 (de)
WO (1) WO2002051401A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071421A2 (en) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries Ltd. Sustained release formulation of n-(2-propylpentanoyl) glycinamide and related compounds
WO2006025029A2 (en) * 2004-08-31 2006-03-09 Ranbaxy Laboratories Limited Extended release composition of divalproex
EP2181708A1 (de) 2008-10-31 2010-05-05 Universitat Autonoma de Barcelona Verwendung von Valproat zur Reduktion der CHOP-Spiegel, insbesondere ein einem Säugetier mit SCI
EP2403487A2 (de) * 2009-03-04 2012-01-11 Fdc Limited Orale darreichungsformen mit verzögerter freisetzung für wasserlösliche arzneimittel
CN102895201B (zh) * 2011-07-26 2014-09-10 北大方正集团有限公司 丙戊酸半钠片剂及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU83729A1 (fr) * 1981-11-04 1983-09-01 Galephar Sels d'acide valproique,leur preparation et leur utilisation
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
FR2643556B1 (fr) * 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
ATE183642T1 (de) * 1991-10-04 1999-09-15 Yoshitomi Pharmaceutical Tablette mit verzögerter freisetzung
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US6419953B1 (en) * 1998-12-18 2002-07-16 Abbott Laboratories Controlled release formulation of divalproex sodium
US6713086B2 (en) * 1998-12-18 2004-03-30 Abbott Laboratories Controlled release formulation of divalproex sodium
SI20624A (sl) * 1998-12-18 2002-02-28 Abbott Laboratories Formulacija divalproeks natrija za kontrolirano sproščanje
US6528090B2 (en) * 1998-12-18 2003-03-04 Abbott Laboratories Controlled release formulation of divalproex sodium
US6511678B2 (en) * 1998-12-18 2003-01-28 Abbott Laboratories Controlled release formulation of divalproex sodium
US6150410A (en) * 1999-02-04 2000-11-21 Abbott Laboratories pH independent extended release pharmaceutical formulation
DK1146864T3 (da) * 1999-02-04 2009-05-11 Abbott Lab pH-uafhængig farmaceutisk formulering med forlænget frisætning

Also Published As

Publication number Publication date
CA2399532A1 (en) 2004-02-23
EP1216704A1 (de) 2002-06-26
EP1216704B1 (de) 2004-09-08
WO2002051401A3 (en) 2003-01-09
TR200402549T4 (tr) 2004-12-21
WO2002051401A2 (en) 2002-07-04
DE60105381D1 (de) 2004-10-14
ES2228762T3 (es) 2005-04-16
US20020025341A1 (en) 2002-02-28
PT1216704E (pt) 2004-11-30
AU2002239260A1 (en) 2002-07-08
DE60105381T2 (de) 2005-09-29

Similar Documents

Publication Publication Date Title
CY1105908T1 (el) Στοματικως αποσαθρουμενα δισκια που πepιλαμβανουν βενζιμιδαζολιο
NZ314442A (en) Extended release formulation comprising venlafaxine hydrochloride, film coating composition
CA2427815A1 (en) Controlled release hydrocodone formulations
CA2301378A1 (en) Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
BG104620A (en) Oral pharmaceutical extended release dosage form
ES2125099T3 (es) Composiciones que comprenden nanoparticulas de un antiinflamatorio no estereoideo.
IL129870A (en) Sustained release tablets having an insoluble active ingredient therein
TNSN03108A1 (en) Once-a-day oxycodone formulations
TWI235068B (en) Sustained-release pharmaceutical composition
HUP9900231A2 (hu) Szabályozott kibocsátású készítmények gyengén oldódó gyógyszerekhez
WO2003013433A3 (en) Sequestered antagonist formulations
HK1031325A1 (en) Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
DE59908764D1 (de) Agitationsunabhängige pharmazeutische multiple-unit-retardzubereitungen und verfahren zu ihrer herstellung
CA2330480A1 (en) Controlled release formulation of divalproex sodium
AR021806A1 (es) COMPOSICIoN FARMACÉUTICA EN FORMA DE TABLETA QUE COMPRENDE ENTACAPONA Y MÉTODO DE PREPARACIoN.
AP2003002763A0 (en) Controlled release formulations for oral administration
ATE430561T1 (de) Chronotherapeutische diltiazem formulierungen und deren verabreichung
HUP9902878A2 (hu) Trimebutin-maleát filmtabletta
CA2507743A1 (en) Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles
ATE275398T1 (de) Valproat-formulierungen mit gesteuerter freigabe
SE9501671D0 (sv) Method and composition for prevention of posterior capsule opacification
HRP20000704B1 (en) Controlled release peroral compositions of levosimendan
CA2341805A1 (en) Controlled release formulation of divalproex sodium
CA2341803A1 (en) Controlled release formulation of divalproex sodium
DK0557244T3 (da) Dosisformer med forlænget afgivelse af aktivt stof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1216704

Country of ref document: EP